| Business: |
Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTC Pink Market. This is also a public offering of units..
We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. (Incorporated in Delaware)
Utilizing our scientific and oncology consultants, we have developed a rational composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.
Risks associated with our Business
Our ability to execute our future business growth strategy is subject to numerous risks, as more fully described in the section captioned “Risk Factors” immediately following this prospectus summary. An investment in our Units involves a high degree of risk. You should carefully consider the risks summarized below. These risks are discussed more fully in the section titled “Risk Factors” following this prospectus summary. These risks include, but are not limited to, the following:
|
● |
Because PRP remains in the early stages of development and may never become commercially viable, you may lose some or all of your investment. |
|
● |
PRP may cause undesirable side effects that could negatively impact its clinical trial results or limit its use, hindering further development, subject us to possible product liability claims, and make it more difficult to commercialize PRP |
|
● |
Because successful development of our products is uncertain, our results of operations may be materially harmed. |
|
● |
A variety of factors, either alone or in concert with each other, could result in our clinical trials of PRP being delayed or unsuccessful. |
|
● |
If we fail to obtain regulatory approval in jurisdictions outside the U.S., we will not be able to market PRP in those jurisdictions. |
|
● |
If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market PRP, we may not be successful in commercializing our product candidates if and when they are approved. |
|
● |
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. |
|
● |
Even if we are able to commercialize PRP, we will need to seek approval for reimbursement before it can be marketed, and it may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. |
Note: Net loss and revenue figures are for the year that ended June 30, 2024.
(Note: Propanc Biopharma Inc. filed its S-1 on Oct. 30, 2024, and unveiled some of the terms for its unit public offering, which it’s planning in conjunction with the proposed uplisting of its common stock to the NASDAQ: 1.5 million units – at a price to be determined – to raise about $9 million.)
|
